In support of this notion, interestingly, NSCLC patients who display both EGFR activating mutation(s) and SHCBP1 upregulation exhibit worse clinical outcome as compared with those with only EGFR activating mutation or SHCBP1 upregulation alone, suggesting a cooperative effect of EGFR activation and SHCBP1 upregulation on tumor progression. This evidence concerns the gene SHCBP1 and neoplasm.